NewVac Reports Primary Endpoint Met in Phase II Clinical Trial of Quisinostat in Platinum-Resistant Ovarian Cancer

Title: NewVac’s Quisinostat Achieves Primary Endpoint in Phase II Trial for Platinum-Resistant Ovarian Cancer


Introduce the recent milestone achieved by NewVac in their Phase II clinical trial, where Quisinostat demonstrated positive results in treating platinum-resistant ovarian cancer patients. Emphasize the significance of this development in providing new hope for patients with limited treatment options.

Key Point 1: The Challenge of Platinum-Resistant Ovarian Cancer:

Discuss the difficulties in treating platinum-resistant ovarian cancer, as the disease often shows resistance to standard platinum-based chemotherapy. Note the need for alternative treatment options to improve outcomes for these patients.

Key Point 2: Overview of Quisinostat:

Provide an overview of Quisinostat, detailing its mechanism of action as a histone deacetylase inhibitor (HDACi) and its potential as a targeted therapy for overcoming platinum resistance.

Key Point 3: Positive Results in Phase II Clinical Trial:

Highlight the positive outcome of the Phase II clinical trial conducted by NewVac, where Quisinostat successfully met its primary endpoint. Illustrate the significant improvement in progression-free survival (PFS) and overall response rate (ORR) observed in patients treated with Quisinostat compared to standard therapy.

Key Point 4: Implications for Patient Care:

Discuss how the successful results of the trial hold promise for improving treatment options for platinum-resistant ovarian cancer patients. Emphasize the potential of Quisinostat to be a valuable addition to the current therapeutic arsenal, potentially enhancing patient outcomes and quality of life.

Key Point 5: Future Prospects and Next Steps:

Explore the future prospects for Quisinostat and NewVac, including potential regulatory milestones and further clinical development. Discuss the importance of continued research and larger-scale trials to validate the efficacy and safety of Quisinostat in a broader patient population.

Key Point 6: Impact on Ovarian Cancer Treatment:

Highlight how the success of Quisinostat in platinum-resistant ovarian cancer can potentially pave the way for future developments in the field. Discuss the potential for Quisinostat to be used in combination therapies or as part of personalized treatment approaches to further improve clinical outcomes.

Key Point 7: Patient Perspective and Support:

Acknowledge the importance of patient support and participation in clinical trials, highlighting the brave individuals who participated in the Phase II study. Discuss the potential positive impact of Quisinostat on the lives of patients battling platinum-resistant ovarian cancer.


Recap the key points discussed in the blog post, emphasizing the significant milestone achieved by NewVac with Quisinostat in their Phase II clinical trial for platinum-resistant ovarian cancer. Highlight the potential of Quisinostat to address a critical unmet need in ovarian cancer treatment and improve patient outcomes. Express optimism for the future development and availability of Quisinostat, and encourage further advancements in targeted therapies to combat this challenging disease.